Back to search

Article

Thymus Composition Predicts Pneumonitis Risk in Lung Cancer Therapy

2025-10-29

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Durvalumab consolidation after concurrent chemoradiotherapy (cCRT) is the standard-of-care for unresectable stage III non–small cell lung cancer (NSCLC) without actionable driver mutations. However, pneumonitis remains a dose-limiting toxicity that often precludes or interrupts immunotherapy. Conventional predictors based on lung dosimetry alone exhibit limited individual-le...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ad901090-73ed-56b6-9316-e19052d688de
DOI
10.1101/2025.10.27.25338565
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Thymus Composition Predicts Pneumonitis Risk in Lung Cancer TherapyDOI 10.1101/2025.10.27.25338565
Select a neighboring publication to make it the new centre.